LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences:
- The Wells Fargo Securities 2018 Healthcare Conference on September 5, 2018 at 10:15 a.m. ET in Boston;
- The H.C. Wainwright 20th Annual Global Investment Conference on September 6, 2018 at 10:00 a.m. ET in New York;
- The Janney Montgomery Scott Healthcare Conference 2018 on September 17, 2018 at 9:05 a.m. ET in New York; and
- The 2018 Cantor Global Healthcare Conference on October 3, 2018 at 10:20 a.m. ET in New York.
A live webcast of these presentations may be accessed in the Investors section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the investor conference webcasts will be available on Concert’s website for two weeks following each presentation.
About Concert
Concert
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to treat serious diseases and address unmet patient
needs. The Company’s approach starts with previously studied compounds,
including approved drugs, in which deuterium substitution has the
potential to enhance clinical safety, tolerability or efficacy. Concert
has a broad
pipeline of innovative medicines targeting autoimmune and
inflammatory diseases and central nervous systems (CNS) disorders. For
more information please visit www.concertpharma.com
or follow us on Twitter at @ConcertPharma
or on LinkedIn.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
